University of California, Los Angeles.
Arthritis Rheumatol. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204.
An increased frequency of atherosclerosis (ATH) in systemic lupus erythematosus (SLE) is well-documented but not fully explained by the presence of traditional cardiac risk factors. Several nontraditional biomarkers, including proinflammatory high-density lipoprotein (piHDL) and leptin, have been individually associated with subclinical ATH in SLE. The aim of this study was to examine whether these and other biomarkers can be combined into a risk profile, the Predictors of Risk for Elevated Flares, Damage Progression, and Increased Cardiovascular Disease in Patients with SLE (PREDICTS), that could be used to better predict future progression of ATH.
In total, 210 patients with SLE and 100 age-matched healthy control subjects (all women) participated in this prospective cohort study. The longitudinal presence of carotid plaque and intima-media thickness (IMT) were measured at baseline and followup (mean ± SD 29.6 ± 9.7 months).
At followup, carotid plaque was present in 29% of SLE patients. Factors significantly associated with plaque, determined using Salford Predictive Modeling and multivariate analysis, included age ≥48 years (odds ratio [OR] 4.1, P = 0.002), high piHDL function (OR 9.1, P < 0.001), leptin levels ≥34 ng/dl (OR 7.3, P = 0.001), plasma soluble TWEAK levels ≥373 pg/ml (OR 28.8, P = 0.004), and history of diabetes (OR 61.8, P < 0.001). Homocysteine levels ≥12 μmoles/liter were also a predictor. However, no single variable demonstrated an ideal combination of good negative predictive values (NPVs), positive predictive values (PPVs), sensitivity, and specificity. A high-risk PREDICTS profile was defined as ≥3 positive biomarkers or ≥1 positive biomarker plus a history of diabetes; for high-risk SLE patients, the PPV was 64%, NPV was 94%, sensitivity was 89%, and specificity was 79%. In multivariate analysis, SLE patients with the high-risk profile had 28-fold increased odds for the longitudinal presence of plaque (P < 0.001) and increased progression of IMT (P < 0.001).
A high-risk PREDICTS score confers 28-fold increased odds of the presence of any current, progressive, or acquired carotid plaque, both in patients with SLE and in control subjects, and is significantly associated with higher rates of IMT progression.
系统性红斑狼疮(SLE)患者动脉粥样硬化(ATH)的发病率增加,这一现象不能仅用传统的心脏危险因素来解释,这一现象已得到充分证实。几种非传统的生物标志物,包括促炎型高密度脂蛋白(piHDL)和瘦素,已被单独证明与 SLE 患者的亚临床 ATH 有关。本研究旨在探讨这些和其他生物标志物是否可以组合成一个风险模型,即预测系统性红斑狼疮患者发生 flares、损伤进展和心血管疾病风险的生物标志物(Predictors of Risk for Elevated Flares, Damage Progression, and Increased Cardiovascular Disease in Patients with SLE,PREDICTS),以便更好地预测 ATH 的未来进展。
本前瞻性队列研究共纳入 210 例 SLE 患者和 100 名年龄匹配的健康对照者(均为女性)。在基线和随访时(平均随访时间为 29.6±9.7 个月),测量颈动脉斑块和内-中膜厚度(IMT)的纵向变化。
随访时,29%的 SLE 患者存在颈动脉斑块。使用 Salford 预测模型和多变量分析确定与斑块相关的因素包括年龄≥48 岁(比值比[OR] 4.1,P=0.002)、高 piHDL 功能(OR 9.1,P<0.001)、瘦素水平≥34ng/dl(OR 7.3,P=0.001)、血浆可溶性 TWEAK 水平≥373pg/ml(OR 28.8,P=0.004)和糖尿病史(OR 61.8,P<0.001)。同型半胱氨酸水平≥12μmol/L 也是一个预测指标。然而,没有任何单一变量能够同时表现出良好的阴性预测值(NPV)、阳性预测值(PPV)、敏感性和特异性的理想组合。高风险 PREDICTS 模型定义为≥3 个阳性生物标志物或≥1 个阳性生物标志物加糖尿病史;对于高风险 SLE 患者,PPV 为 64%,NPV 为 94%,敏感性为 89%,特异性为 79%。在多变量分析中,具有高风险模型的 SLE 患者发生斑块的可能性增加了 28 倍(P<0.001),且 IMT 进展的可能性也增加了(P<0.001)。
高风险的 PREDICTS 评分使 SLE 患者和健康对照者的当前、进展性或获得性颈动脉斑块的发生风险增加了 28 倍,且与 IMT 进展率的升高显著相关。